The Orphan Drug Act and the Myth of the Exclusivity Incentive

by Robert Rogoyski, J.D.

7 Colum. Sci. & Tech. L. Rev. 4 (2006) (Published April 15, 2006)

Abstract

For more than 20 years, the marketing exclusivity provision of the Orphan Drug Act has been hailed as a key component of the incentive for the United States’ pharmaceutical industry to develop drugs for rare disorders; this is the Official Story of the ODA. In this paper, I argue that the Official Story is a myth. Rather, the real engine for the development of drugs to treat rare disorders is the patent system.

About the Author

Robert Rogoyski: J.D. cum laude, Harvard Law School, 2005.

Important Note

For proper legal citation of this document, please cite to the following URL: http://www.stlr.org/cite.cgi?volume=7&article=4. The URL that currently appears in your browser’s location toolbar is incorrect. For more information on Bluebook citation of internet sources, click here.

View in PDF

blog comments powered by Disqus